Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05010005 · ClinicalTrials.gov registry record · Phase 1
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
A Phase 1 study of T-cell-prolymphocytic Leukemia and T-cell Large Granular Lymphocyte Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 9
- Study locations
NCT05010005 is a Phase 1 study of T-cell-prolymphocytic Leukemia and T-cell Large Granular Lymphocyte Leukemia that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 70 participants, below the 171-participant average among 7 other T-cell-prolymphocytic Leukemia trials with a reported enrollment target (59% lower). The trial reports 9 study locations across 4 states.
The verdict
NCT05010005, a Phase 1 study of T-cell-prolymphocytic Leukemia and T-cell Large Granular Lymphocyte Leukemia, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma. This study has three parts: dose escalation (Part 1), dose expansion (Part 2), and TFH/T-PLL cohort expansion (Part 3).
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Duvelisib
Study Locations (9)
New York
- Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Florida
- University of Miami (Data Collection Only) - Miami
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-08-12 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05010005
The ClinicalTrials.gov registry entry for NCT05010005 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 7 other T-cell-prolymphocytic Leukemia trials with a reported enrollment target (59% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with T-cell-prolymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT05010005 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Florida.
Frequently Asked Questions
What is clinical trial NCT05010005 about?
NCT05010005 is a clinical study titled "A Study of Ruxolitinib and Duvelisib in People With Lymphoma". This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma. This study has three parts: dose escalation (P...
What is the current status of trial NCT05010005?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2021-08-12. Estimated completion is 2027-08.
What conditions does trial NCT05010005 study?
This clinical trial studies the following conditions: T-cell-prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia, T-cell Lymphomas, NK-Cell Lymphomas.
What interventions are being tested in trial NCT05010005?
The interventions under investigation include: Ruxolitinib (DRUG), Duvelisib (DRUG).
Who is sponsoring clinical trial NCT05010005?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05010005 being conducted?
This trial has 9 study locations across Florida, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell-prolymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
RECRUITING · Phase 1
-
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RECRUITING · Phase 1
-
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
ACTIVE NOT RECRUITING · Phase 1
-
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Registry for People With T-cell Lymphoma
RECRUITING
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
T-cell-prolymphocytic Leukemia
All registered trials for this condition
T-cell Large Granular Lymphocyte Leukemia
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.